NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Trabectedin (Primary) ; Doxorubicin liposomal
- Indications Carcinoma; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms NIMES-ROC
- Sponsors PharmaMar
- 30 Jun 2020 Status changed from active, no longer recruiting to completed.
- 04 Nov 2019 According to a PharmaMar Media Release, data from this trial were presented at the European Congress of Oncological Gynecology (ESGO), being held from 2-5 November in Athens, Greece.
- 04 Nov 2019 Results presented in a PharmaMar Media Release.